Knight Therapeutics and SIFI Announce Filing of New Drug Submission

Knight Therapeutics (TSX:GUD) a leading Canadian specialty pharmaceutical company, and S.I.F.I- Società Industria Farmaceutica Italiana S.p.A., a prominent Italian Eye Care company, today announced that Knight’s New Drug Submission for NETILDEX™ has been accepted for review by Health Canada. NETILDEX™ is a fixed combination of netilmicin and dexamethasone for the treatment of inflammatory ocular conditions of the anterior segment of the eye, including post-operative cases, where bacterial infection or a risk of bacterial infection exists.

As quoted in the press release:

“We are excited about filing NETILDEX™ in Canada and moving closer to providing Canadians with an innovative pharmaceutical that contains a new antibiotic with a well-established corticosteroid,” said Jonathan Ross Goodman, Chief Executive Officer of Knight.

“We look forward to working with Knight and Canadian regulators in an effort to expand the availability of our novel product for Canadian patients and physicians, which would represent a key milestone in establishing NETILDEX™ as a global brand in this reference market” said Mr. Fabrizio Chines, Chairman and Chief Executive Officer of SIFI.

Click here to read the full press release.